<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536742</url>
  </required_header>
  <id_info>
    <org_study_id>IBCSG 53-14 / BIG 14-04</org_study_id>
    <secondary_id>2014-005387-15</secondary_id>
    <secondary_id>WI198393</secondary_id>
    <nct_id>NCT02536742</nct_id>
  </id_info>
  <brief_title>Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer</brief_title>
  <acronym>PYTHIA</acronym>
  <official_title>A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This international, multicenter, prospective single arm Phase II biomarker discovery clinical
      trial with the primary objective of assessing the association of PFS with gene mutations,
      gene copy number aberrations and gene signatures in post-menopausal women with hormone
      receptor positive, HER2-negative metastatic or locally relapsed breast cancer whose disease
      has progressed after prior adjuvant endocrine therapy or one line systemic treatment, i.e.,
      endocrine treatment or chemotherapy, administered for metastatic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be treated with the combination of palbociclib and fulvestrant. The primary
      objective is to assess the association of the primary endpoint progression-free survival
      (PFS) with potential markers.

      The trial is included in the AURORA program conducted by the Breast International Group
      (BIG), an international study aiming to collect and characterize biological samples,
      including metastatic tissue, from patients with advanced breast cancer.

      The primary aim of the PYTHIA study is to discover potentially innovative biomarkers for the
      selection of patients to Palbociclib/Fulvestrant treatment. The strength of the trial lies in
      its conduct in conjunction with the AURORA study, which systematically evaluates a panel of
      biomarkers in tissue and blood, in a certified central lab. Stemming from this association,
      an abundance of molecular profiling information will become available for different
      biological samples. Additional molecular and functional imaging assessments performed within
      the context of the PYTHIA study increase its scientific merit, since it will represent a
      prospective, systematic effort to identify biomarkers for patient stratification, integrating
      several molecular profiling assessments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Maximal 36 months</time_frame>
    <description>Time from treatment initiation until documented disease progression according to RECIST 1.1 or death, whichever occurs first</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib plus Fulvestrant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>PD-0332991</other_name>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female gender

          -  Age ≥ 18 years

          -  Postmenopausal, defined as women with:

               -  Prior bilateral surgical oophorectomy; or

               -  Amenorrhea and age ≥ 60 years; or

               -  Age &lt; 60 years and amenorrhea for 12 or more consecutive months in the absence of
                  alternative pathological or physiological cause and FSH and serum estradiol
                  levels within the laboratory's reference ranges for postmenopausal women.

          -  Endocrine resistant disease, defined as one of:

               -  Relapse while on adjuvant endocrine therapy;

               -  Relapse within 12 months after completion of adjuvant endocrine therapy;

               -  Progression of disease under first line endocrine therapy for metastatic and/or
                  loco-regionally advanced breast cancer.

        Note: Patient may have received one prior chemotherapy for advanced or metastatic breast
        cancer.

          -  ER positive tumor and HER2-negative tumor, as assessed locally

          -  ECOG Performance Status 0-1.

          -  Measurable or non-measurable but evaluable disease according to RECIST 1.1.

          -  Written Informed Consent (IC) for screening procedures.

          -  Written informed consent to participate in the AURORA program of BIG.

          -  The patient has been informed of and agrees to data transfer and handling, in
             accordance with national data protection guidelines.

          -  Life expectancy &gt;3 months.

          -  Hematological status:

               -  Absolute neutrophil count ≥ 1.5 × 109/L

               -  Platelet count ≥ 100 × 109/L

               -  Hemoglobin ≥ 9 g/dL

          -  Hepatic status:

               -  Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN).

               -  AST and ALT ≤ 2.5 × ULN; if the patient has liver metastases, ALT and AST must be
                  ≤ 5 × ULN.

          -  Glucose in normal range, or well-controlled diabetes defined as an HbA1c level ≤ 7.5%.

          -  Renal status:

             - Creatinine ≤ 1.5 ×ULN or creatinine clearance &gt; 60 ml/min.

          -  International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 × ULN unless
             patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic
             range of intended use of anticoagulant.

          -  Ability to swallow oral medication.

        Exclusion Criteria:

          -  Prior use of fulvestrant or any CDK inhibitor.

          -  More than one prior line of chemotherapy for metastatic or locally relapsed disease.

          -  Previous or current non-breast malignancies within the last 5 years, with the
             exception of in situ carcinoma of the cervix, and adequately treated basal cell or
             squamous cell carcinoma of the skin.

          -  Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis or
             leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or
             progressive growth.

          -  Any of the following in the previous 6 months: myocardial infarction, severe/unstable
             angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial
             fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic
             congestive heart failure (NYHA functional classification ≥3), cerebrovascular accident
             including transient ischemic attack, or symptomatic pulmonary embolism.

          -  QTc exceeding 480msec, family or personal history of long or short QT syndrome,
             Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP).

          -  Uncontrolled electrolyte disorders that can reinforce the QT-prolonging effect of the
             drug (e.g., hypocalcemia, hypokalemia, hypomag¬nesemia).

          -  Known history of HIV seropositivity. HIV screening is not required at baseline.

          -  Uncontrolled diabetes defined as HbA1c level &gt; 7.5%.

          -  Concurrent disease or familial, sociological or geographical condition that would make
             the patient inappropriate for trial participation or any serious medical disorder that
             would interfere with the patient's safety.

          -  Dementia, altered mental status, or any psychiatric condition that would prevent the
             understanding or rendering of Informed Consent.

          -  Known abnormalities in coagulation such as bleeding diathesis, or treatment with
             anticoagulants precluding intramuscular injections of fulvestrant.

          -  Treatment with an investigational agent in the 4 weeks before enrollment.

          -  Concurrent treatment with any of the drugs not permitted

          -  Adverse events (except alopecia) from previous systemic cancer therapy, radiotherapy
             or surgery have not recovered to CTCAE v4.0 grade 1 or resolved prior to enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Malorni, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>USL4 Hospital of Prato, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Poonam Jani</last_name>
    <phone>+1 716-834-0900</phone>
    <email>ibcsg53_PYTHIA@fstrf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sint-Augustinus</name>
      <address>
        <city>Antwerpen</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Dirix</last_name>
      <email>cto@gza.be</email>
    </contact>
    <investigator>
      <last_name>Luc Dirix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bodet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michail Ignatiadis</last_name>
      <email>michail.ignatiadis@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Michail Ignatiadis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Duhoux</last_name>
      <email>francois.duhoux@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Francois Duhoux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Papadimitriou</last_name>
    </contact>
    <investigator>
      <last_name>Konstantinos Papadimitriou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Neven</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Neven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liege</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Jerusalem</last_name>
      <email>g.jerusalem@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Guy Jerusalem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique St. Elizabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Vuylsteke</last_name>
      <email>peter.vuylsteke@cmsenamur.be</email>
    </contact>
    <investigator>
      <last_name>Peter Vuylsteke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali degli Infermi, S.O.C. Oncologia</name>
      <address>
        <city>Biella</city>
        <zip>13879</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Seles, MD</last_name>
      <email>seles.e@libero.it</email>
    </contact>
    <investigator>
      <last_name>Elena Seles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Centrale Bolzano, Medical Oncology</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Graiff</last_name>
      <email>claudio.graiff@sabes.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Graiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS San Martino University Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Ballestrero</last_name>
      <email>aballestrero@unige.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Ballestrero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Salutis Hospital AULSS 21 della Regione Veneto</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bonetti</last_name>
      <email>andrea.bonetti@aulsslegnago.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Bonetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Colleoni</last_name>
      <email>marco.colleoni@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Marco Colleoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituti Clinici Scientifici Maugeri, Medical Oncology Unit</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Bernardo</last_name>
      <email>antonio.bernardo@icsmaugeri.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Bernardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda USL4 Prato</name>
      <address>
        <city>Prato</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Malorni</last_name>
      <email>lmalorni@usl4.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Luca Malorni, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeremy Braybrooke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre NHS Trust</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jacinta Abraham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dave Cameron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Iain Macpherson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gianfilippo Bertelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alastair Thomson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <link>
    <url>http://www.ibcsg.org</url>
    <description>Sponsor</description>
  </link>
  <reference>
    <citation>Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010 Jul 8;29(27):3896-907. doi: 10.1038/onc.2010.151. Epub 2010 May 10.</citation>
    <PMID>20453888</PMID>
  </reference>
  <reference>
    <citation>Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.</citation>
    <PMID>25524798</PMID>
  </reference>
  <reference>
    <citation>Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.</citation>
    <PMID>26030518</PMID>
  </reference>
  <reference>
    <citation>Di Leo A, Malorni L. Polyendocrine treatment in estrogen receptor-positive breast cancer: a &quot;FACT&quot; yet to be proven. J Clin Oncol. 2012 Jun 1;30(16):1897-900. doi: 10.1200/JCO.2012.41.7394. Epub 2012 Apr 30.</citation>
    <PMID>22547606</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>Palbociclib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

